Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

September 9, 2018

Primary Completion Date

March 31, 2023

Study Completion Date

October 3, 2025

Conditions
Juvenile Myelomonocytic LeukemiaNeurofibromatosis Type 1
Interventions
PROCEDURE

Bone Marrow Aspiration and Biopsy

Undergo bone marrow aspiration or biopsy

DRUG

Trametinib

Given PO

Trial Locations (57)

10029

Mount Sinai Hospital, New York

10032

NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York

11040

The Steven and Alexandra Cohen Children's Medical Center of New York, New Hyde Park

15224

Children's Hospital of Pittsburgh of UPMC, Pittsburgh

19104

Children's Hospital of Philadelphia, Philadelphia

19803

Alfred I duPont Hospital for Children, Wilmington

20007

MedStar Georgetown University Hospital, Washington D.C.

20010

Children's National Medical Center, Washington D.C.

20892

National Institutes of Health Clinical Center, Bethesda

27710

Duke University Medical Center, Durham

28203

Carolinas Medical Center/Levine Cancer Institute, Charlotte

29605

BI-LO Charities Children's Cancer Center, Greenville

30329

Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta

32207

Nemours Children's Clinic-Jacksonville, Jacksonville

32806

Arnold Palmer Hospital for Children, Orlando

32827

Nemours Children's Hospital, Orlando

33136

University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami

33155

Nicklaus Children's Hospital, Miami

33607

Saint Joseph's Hospital/Children's Hospital-Tampa, Tampa

35233

Children's Hospital of Alabama, Birmingham

37203

The Children's Hospital at TriStar Centennial, Nashville

37232

Vanderbilt University/Ingram Cancer Center, Nashville

38105

Saint Jude Children's Research Hospital, Memphis

40536

University of Kentucky/Markey Cancer Center, Lexington

43205

Nationwide Children's Hospital, Columbus

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

45404

Dayton Children's Hospital, Dayton

46202

Riley Hospital for Children, Indianapolis

48109

C S Mott Children's Hospital, Ann Arbor

52242

University of Iowa/Holden Comprehensive Cancer Center, Iowa City

53226

Children's Hospital of Wisconsin, Milwaukee

55404

Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis

55455

University of Minnesota/Masonic Cancer Center, Minneapolis

60611

Lurie Children's Hospital-Chicago, Chicago

61637

Saint Jude Midwest Affiliate, Peoria

63110

Washington University School of Medicine, St Louis

64108

Children's Mercy Hospitals and Clinics, Kansas City

73104

University of Oklahoma Health Sciences Center, Oklahoma City

75390

UT Southwestern/Simmons Cancer Center-Dallas, Dallas

77030

Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston

78229

Methodist Children's Hospital of South Texas, San Antonio

78723

Dell Children's Medical Center of Central Texas, Austin

80045

Children's Hospital Colorado, Aurora

80218

Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center, Denver

84113

Primary Children's Hospital, Salt Lake City

85016

Phoenix Childrens Hospital, Phoenix

90242

Kaiser Permanente Downey Medical Center, Downey

92354

Loma Linda University Medical Center, Loma Linda

92868

Children's Hospital of Orange County, Orange

94158

UCSF Medical Center-Mission Bay, San Francisco

94304

Lucile Packard Children's Hospital Stanford University, Palo Alto

94611

Kaiser Permanente-Oakland, Oakland

97239

Oregon Health and Science University, Portland

98105

Seattle Children's Hospital, Seattle

72202-3591

Arkansas Children's Hospital, Little Rock

06106

Connecticut Children's Medical Center, Hartford

02215

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

Children's Oncology Group

NETWORK

lead

National Cancer Institute (NCI)

NIH

NCT03190915 - Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia | Biotech Hunter | Biotech Hunter